Potential for targeted therapy in prostate cancers with ERG abnormalities  

作　　者：Sean R Williamson Liang Cheng 

机构地区：[1]Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA [2]Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA

出　　处：《Asian Journal of Andrology》2011年第6期781-782,共2页亚洲男性学杂志（英文版）

摘　　要：Since the recent identification of recurrent gene fusions in prostate cancer betweenmembers of the ETS family of genes and transmembrane protease, serine 2 （TM PRSS2）, a tremendous amount of interest has developed in the pathways through which these fusions contribute to prostatic carcinogenesis, as well as their diaenostic utilitv.Since the recent identification of recurrent gene fusions in prostate cancer betweenmembers of the ETS family of genes and transmembrane protease, serine 2 （TM PRSS2）, a tremendous amount of interest has developed in the pathways through which these fusions contribute to prostatic carcinogenesis, as well as their diaenostic utilitv.

分 类 号：Q78[生物学—分子生物学] Q517